2015/16 to 2017/18 influenza seasons by Machado, Ausenda et al.
1www.eurosurveillance.org
Research
Impact of influenza vaccination programmes among the 
elderly population on primary care, Portugal, Spain and 
the Netherlands: 2015/16 to 2017/18 influenza seasons
Ausenda Machado1,2,3, Clara Mazagatos2,4, Frederika Dijkstra2,5, Irina Kislaya1,3, Alin Gherasim4, Scott A McDonald5, Esther 
Kissling6, Marta Valenciano6, Adam Meijer5, Mariëtte Hooiveld7, Baltazar Nunes1,3, Amparo Larrauri4
1. National Institute for Health Doutor Ricardo Jorge, Epidemiology department, Lisbon, Portugal
2. These authors contributed equally
3. NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa, Lisbon, Portugal
4. National Centre of Epidemiology, Carlos III Health Institute, CIBER of Epidemiology and Public Health (CIBERESP), Madrid, 
Spain
5. National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
6. Epidemiology department, Epiconcept, Paris, France
7. Nivel, Netherlands Institute for Health Services Research, Utrecht, the Netherlands
Correspondence: Ausenda Machado (ausenda.machado@insa.min-saude.pt)
Citation style for this article: 
Machado Ausenda, Mazagatos Clara, Dijkstra Frederika, Kislaya Irina, Gherasim Alin, McDonald Scott A, Kissling Esther, Valenciano Marta, Meijer Adam, Hooiveld 
Mariëtte, Nunes Baltazar, Larrauri Amparo. Impact of influenza vaccination programmes among the elderly population on primary care, Portugal, Spain and the 
Netherlands: 2015/16 to 2017/18 influenza seasons. Euro Surveill. 2019;24(45):pii=1900268. https://doi.org/10.2807/1560-7917.ES.2019.24.45.1900268 
Article submitted on 30 Apr 2019 / accepted on 23 Sep 2019 / published on 07 Nov 2019
Background: To increase the acceptability of influenza 
vaccine, it is important to quantify the overall bene-
fits of the vaccination programme. Aim: To assess the 
impact of influenza vaccination in Portugal, Spain and 
the Netherlands, we estimated the number of medi-
cally attended influenza-confirmed cases (MAICC) 
in primary care averted in the seasons 2015/16 to 
2017/18 among those ≥ 65 years. Methods: We used an 
ecological approach to estimate vaccination impact. 
We compared the number of observed MAICC (n) to 
the estimated number that would have occurred with-
out the vaccination programme (N). To estimate N, we 
used: (i) MAICC estimated from influenza surveillance 
systems, (ii) vaccine coverage, (iii) pooled (sub)type-
specific influenza vaccine effectiveness estimates for 
seasons 2015/16 to 2017/18, weighted by the propor-
tion of virus circulation in each season and country. We 
estimated the number of MAICC averted (NAE) and the 
prevented fraction (PF) by the vaccination programme.
Results: The annual average of NAE in the population 
≥ 65 years was 33, 58 and 204 MAICC per 100,000 in 
Portugal, Spain and the Netherlands, respectively. On 
average, influenza vaccination prevented 10.7%, 10.9% 
and 14.2% of potential influenza MAICC each season 
in these countries. The lowest PF was in 2016/17 (4.9–
6.1%) with an NAE ranging from 24 to 69 per 100,000.
Conclusions: Our results suggest that influenza vacci-
nation programmes reduced a substantial number of 
MAICC. Together with studies on hospitalisations and 
deaths averted by influenza vaccination programmes, 
this will contribute to the evaluation of the impact of 
vaccination strategies and strengthen public health 
communication.
Background
Influenza infections cause considerable morbidity and 
mortality [1,2], in particular among the elderly popula-
tion 65 years and older. Vaccination is considered the 
most important public health intervention to reduce the 
incidence of seasonal influenza and its associated com-
plications [3]. Following the World Health Organization 
recommendations [4], most European countries have 
a yearly influenza vaccination programme targeting, 
among others, individuals aged 65 years and older [5]. 
In most European Union (EU) countries, vaccine cover-
age (VC) in individuals in high-risk groups is below the 
target of 75% set by the EU Council [6].
To increase the acceptability of the influenza vaccine, 
it is important to assess the benefits of vaccination. 
Since 2008, influenza vaccine effectiveness (IVE) stud-
ies conducted every season in the EU suggest that the 
effectiveness of the vaccine is low to moderate in the 
elderly population [7,8]. These estimates provide use-
ful information for scientists, but could be less compre-
hensible for the general public and for policymakers.
Estimating the impact of the influenza vaccination 
campaign focusing on the overall effect of the vac-
cine in the population has been an approach used by 
several countries [2,9-12]. Preaud et al. took a multi-
country approach at European level [13]. In that study, 
the authors evaluated the public health and economic 
benefits of influenza vaccination, quantifying the pre-
vented cases of influenza, hospitalisations and deaths 
in target groups for vaccination. They used country-
specific data, when available, and interpolated data 
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otherwise, that covered different seasons according 
to the different parameters. These authors quantified 
the differences in the number of influenza-confirmed 
associated events between the population exposed 
and the population not exposed to the vaccination pro-
gramme using three parameters: IVE, VC and number of 
observed events. Impact was expressed as the number 
of influenza associated events averted by the influenza 
vaccination programme. These impact indicators to 
evaluate vaccine performance are easy to understand 
and to interpret.
To compare the number of averted events (NAE) in dif-
ferent countries with similar but not equivalent vac-
cination strategies, it is important to have not only a 
common approach but also harmonised parameter 
criteria. The lack of country-specific data limited the 
comparison of the impact of European influenza vac-
cination programmes [13]. Therefore, we developed a 
common protocol within the I-MOVE+ project [14] with 
a harmonised methodology that could measure, in 
different countries, the impact of the influenza vacci-
nation programme. In this study, we aimed to assess 
the impact of the influenza vaccination programmes 
in Portugal, Spain and the Netherlands, by measuring 
the number of medically attended influenza-confirmed 
cases (MAICC) in primary care averted by vaccination, 
among the population aged 65 years and older, in three 
consecutive seasons (2015/16 to 2017/18). This was 
done by integrating existing estimates into new meas-
ures that may be more meaningful for public health 
policymakers and the public.
Methods
Study design
We developed an ecological study to estimate the 
number of medically attended influenza averted by the 
influenza vaccination programme.
We computed the number of averted events as:
Table 1
Country-specific influenza vaccination programmes and influenza surveillance systems, the Netherlands, Portugal and 
Spain, influenza seasons 2015/16–2017/18
Characteristics Netherlands Portugal Spain
Vaccination programme
Vaccine used Inactivated trivalent vaccine
Target population Population ≥ 60 years and medical risk groups (≥ 6 months-old)
Population ≥ 65 
years and medical 
risk groups (≥ 6 
months-old)
Population ≥ 65 years and 
medical risk groups (≥ 6 
months-old)
Payment Free of charge for the target groups
Free of charge for 
those ≥  65 years in 
public primary care 
units
Free of charge for target 
groups
Place of vaccination Uptake via GPs Uptake at pharmacy or healthcare units
Uptake mainly in public 
primary care units, but 
also in hospitals if needed, 
and in occupational risk 
units of public and private 
organisations
ILI surveillance system
Surveillance network Nivel Primary Care Database – Sentinel Practices Rede Médicos-Sentinela
Spanish Influenza Sentinel 
Surveillance System
ILI case ascertainment 
and swabbing for 
confirmation
Weekly notification by sentinel GPs of cases meeting the 
‘Pel-criteria’ [42]: sudden onset of symptoms AND fever (at 
least 38 °C) AND at least one of the following symptoms: 
cough, rhinorrhoea, sore throat, frontal headache, 
retrosternal pain or myalgia. GPs are recommended to 
swab at least the first two ILI patients attending each 
week.a
Weekly notification by 
sentinel GPs of cases 
meeting the EU ILI 
case definition
Weekly notification by sentinel 
GPs of cases meeting the EU 
ILI case definition [43]. GPs 
are recommended to swab the 
first two patients attending 
each week.
Laboratory confirmation 
of influenza
RT-PCR testing of nasopharyngeal/nose and throat swabs for influenza confirmation. If the test is positive for 
influenza, further tests are performed to determine virus type/subtype/lineage.
Method of estimating 
positivity rate
Number of positive influenza detections among the 
swabbed respiratory samples × (1/sensitivity of RT-PCR); 
 
Sensitivity of RT-PCR = 0.95
Number of positive influenza detections among the 
swabbed respiratory samples
EU: European Union; GP: general practitioner; ILI: influenza-like illness.
a Patients < 65 years of age consulting on Monday through Wednesday and all ILI patients 65 years and older during the whole week.
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NAE=n×VC×IVE1−(VC×IVE)NAE=n×VC×IVE1−(VC×IVE)
where  n  is the number of observed MAICC. To enable 
comparison between countries, NAE was also pre-
sented per 100,000 population. We estimated the 
prevented fraction as PF = NAE/(n + NAE). In addition, 
we calculated number needed to vaccinate (NNV) to 
prevent one MAICC, using methodology described in 
the Supplementary material.
Input data
Influenza vaccination strategy
In the seasons 2015/16 to 2017/18, trivalent inactivated 
influenza vaccines were available for the population 65 
years and older in the three countries. All countries had 
a national seasonal influenza vaccination programme 
in place and influenza vaccination was recommended 
for high-risk individuals (older age groups and individu-
als with chronic medical conditions) (Table 1). Seasonal 
influenza vaccination was recommended free of charge 
to individuals older than 60 years in the Netherlands, 
older than 60 or 65 years (depending on the region) in 
Spain, and 65 years and older in Portugal.
Medically attended influenza-confirmed cases at 
primary care level
To estimate the number of observed MAICC, we com-
bined epidemiological and virological data routinely 
collected by country-specific sentinel influenza sur-
veillance systems (Table 1) during the surveillance 
epidemic period (week 40 to week 20). For Portugal, 
end-of-season cumulative ILI incidence rates in the 
seasons 2015/16 to 2017/18 were adjusted by end-of-
season influenza positivity rate in the respective sea-
son and extrapolated to the national population aged 
65 years and older. For Spain, weekly ILI and positiv-
ity rate were used to obtain ILI and number of positive 
cases. For the Netherlands, the observed number of 
Table 2
Number of ILI, positivity rate and proportion of influenza (sub)types, MAICC, VC and VE among those aged ≥ 65 years, 
Portugal, Spain and the Netherlands, influenza seasons 2015/16–2017/18
2015/16 2016/17 2017/18
n or % 95% CI n or % 95% CI n or % 95% CI
Portugal
ILI (n) 9,161 6,656–12,297 21,646 17,289–26,766 12,366 9,340–16,057
Positivity rate (%) 27.8 20.5–35.1 47.4 40.2–54.5 46.2 43.0–49.3
MAICC (n) 2,547 1,641–3,686 10,261 7,673–13,087 5,708 4,247–7,298
VC (%) 50.1 42.1–58.1 57.5 50.8–64.1 60.8 55.5–65.9
Subtype A(H1N1)pdm09 (%) 90.4 0.2 20.0
Subtype A(H3N2) (%) 1.3 99.6 14.0
Type B (%) 8.3 0.2 66.0
IVE (%) 40.6 22.6–58.6 8.5 −10.9 to 27.9 23.8 10.9–36.8
Spain
ILI (n) 53,534 49,994–57,199 82,602 78,086–87,249 102,839 97,785–107,959
Positivity rate (%) 41.8 36.4–47.2 47.8 42.8–52.8 60.5 56.1–64.8
MAICC (n) 22,349 19,146–25,611 39,422 34,874–44,206 62,113 56,900–67,575
VCa (%) 56.1 55.5 55.7
Subtype A(H1N1)pdm09 (%) 69.9 0.0 7.6
Subtype A(H3N2) (%) 4.0 94.4 25.3
Type B (%) 23.9 0.6 64.9
IVE (%) 34.0 18.5–48.4 9.0 −10.8 to 27.8 20.0 8.8–30.5
Netherlands
ILI (n) 73,250 63,890–83,290 86,700 76,530–97,650 96,300 86,120–106,900
Positivity rateb (%) 34.9 26.3–44.8 38.5 28.6–49.7 67.2 58.2–77.0
MAICC (n) 25,900 15,510–37,740 33,760 20,570–48,840 65,120 48,100–80,770
VC (%) 66.5 59.3–73.1 62.9 56.1–69.2 60.4 53.9–66.5
Subtype A(H1N1)pdm09 (%) 73.5 1.8 2.8
Subtype A(H3N2) (%) 0.0 92.9 18.3
Type B (%) 26.5 5.4 78.9
IVE (%) 37.1 21.7–52.5 9.7 −8.4 to 27.8 19.5 4.7–34.4
CI: confidence interval; ILI: influenza-like illness; IVE: influenza vaccine effectiveness; MAICC: medically attended influenza-confirmed cases; 
VC: vaccine coverage.
a 95% CI not available. VC in Spain calculated from administrative data, dividing the number of administered vaccine doses by the population.
b Adjusted for test sensitivity.
4 www.eurosurveillance.org
MAICC was estimated using a component of an evidence 
synthesis modelling framework that integrates data on 
ILI incidence, influenza positivity rate and sensitivity of 
virological testing and is routinely used for estimating 
seasonal influenza incidence in the Netherlands [15]. 
Virus shedding peaks around 1 to 2 days after onset of 
symptoms, after which – for healthy persons – it usu-
ally declines to undetectable levels 7 days after onset 
of symptoms [15]. Therefore, we restricted the labo-
ratory diagnostic data from the Netherlands to those 
patients diagnosed with ILI from whom a specimen 
had been collected not more than 7 days after symp-
tom onset. For Spain and Portugal this restriction is not 
applied in the surveillance system. In both countries, 
the great majority of ILI patients recruited by sentinel 
general practitioners (GPs) were swabbed within the 
first 7 days after onset of symptoms (> 93%). ILI data 
were obtained from national sentinel GP networks 
(the Dutch Nivel Primary Care Database, the Spanish 
Influenza Sentinel Surveillance System (SISSS) and the 
Portuguese Rede Médicos-Sentinela [16-18] (Table 1).
Vaccine coverage
In the Netherlands, influenza VC in the population aged 
65 and older was estimated using pseudo-anonymised 
data from electronic medical files of GPs participating 
in the Nivel Primary Care Database [19]. The VC point 
estimate as well as 95% confidence intervals (CI) were 
computed using multilevel logistic regression, taking 
into account the clustering of patients in GP practices 
[19]. In Spain, VC in the population aged 65 and older 
was provided by the Spanish Ministry of Health, based 
on administrative data of the number of doses of influ-
enza vaccine administered [20]. In Portugal, VC was 
estimated using data from the 2015/16 and 2016/17 
waves of a population-based telephone survey among 
the non-institutionalised population in mainland 
Portugal [21].
Vaccine effectiveness
We used the IVE among those aged 65 years and older 
estimated in the I-MOVE+ multicentre primary care-
based test-negative design case–control study [22-24]. 
We pooled the VE of three seasons (2015/16–2017/18) 
(Supplementary Table S1) and weighted the (sub)type-
specific VE by the proportion of influenza (sub)type 
detected in primary care settings in each country.
Uncertainty estimation
To estimate the 95% CI for NAE and PF, we used a prob-
abilistic Monte Carlo approach. We constructed empiri-
cal distributions for influenza-associated outcomes, 
positivity rate, IVE and VC and used the 2.5 and 97.5 
percentiles of these empirical distributions to compute 
the 95% CI for NAE and PF. All analyses were performed 
using STATA software.
Ethical statement
The study was based on aggregated data obtained from 
official statistics, influenza surveillance systems and 
epidemiological studies (IVE studies) with scientific 
protocols approved by the national ethical committees 
of the three involved countries. Given the ecological 
nature of the study, no additional ethical approval was 
required.
Results
Input data
Medically attended influenza-confirmed cases at 
primary care level
In seasons 2015/16 and 2016/17, ILI epidemics occurred 
in similar periods in the three countries. In the 2017/18 
season, a longer ILI epidemic was observed in the 
Netherlands (Supplementary Figure S1).
Table 3
Seasonal average, number and rates of MAICC events averted among those aged ≥ 65 years, by season, Portugal, Spain and 
the Netherlands, influenza seasons 2015/16–2017/18
Country Indicator 2015/16 2016/17a 2017/18 Average
Portugal
NAE (95% CI) 650 (265–1,162) 527 (−746 to 1,876) 967 (316–1,701) 715 (215–1,246)
Rate NAE/105 (95% CI) 30 (13–52) 24 (−35 to 85) 44 (15–77) 33 (9.9–57.3)
PF in % (95% CI) 20.3 (10.7–28.4) 4.9 (−7.9 to 15.1) 14.5(5.4–21.9) 10.7 (3.3–16.4)
Spain
NAE (95% CI) 5,268 (2,453–8,224) 2,073 (−2,657 to 6,758)
7,787 
(2,891–12,648) 5,042 (2,602–7,500)
Rate NAE/105 (95% CI) 61 (29–96) 24 (−30 to 78) 88 (33–143) 58 (30–86)
PF in % (95%CI) 19.1 (10.1–26.4) 5.0 (−7.1 to 14.5) 11.1 (4.4–16.9) 10.9 (5.9–15.3)
Netherlands
NAE (95% CI) 8,483 (3,396–16,255) 2,194 (−2,141 to 7,524)
8,694 
(1,158–17,487) 6,457 (2,310–12,013)
Rate NAE/105 (95% CI) 275 (110–527) 69 (−68 to 238) 268 (36–540) 204 (74–380)
PF in % (95% CI) 24.7 (12.7–34.6) 6.1 (−6.7 to 16.8) 11.8 (1.8–20.3) 14.2 (5.2–21.5)
CI: confidence interval; MAICC: medically attended influenza-confirmed cases; NAE: Number of averted MAICC events; PF: prevented fraction.
a Negative lower bounds of 95% CI for NAE, averted rate and PF in 2016/17 season reflect the uncertainty around the point estimates and 
should not be interpreted as ‘negative impact’.
Parameter point estimates from Table 2 were used to calculate the point estimates of NAE, averted rate and PF.
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In all countries, the largest proportion of viruses 
detected in the sentinel networks were influenza 
A(H1N1)pdm09 in 2015/16, influenza A(H3N2) in 
2016/17 and influenza B in 2017/18 (Table 2). The high-
est number of MAICC occurred in 2016/17 and 2017/18.
Vaccine coverage
In the study period, VC in the population aged 65 
years and older ranged between 50.1% (Portugal) and 
66.5% (the Netherlands) (Table 2). The VC increased in 
Portugal (from 50.1% in 2015/16 to 60.8% in 2017/18), 
decreased in the Netherlands (from 66.5% in 2015/16 
to 60.4% in 2017/18) and remained similar in Spain.
Influenza vaccine effectiveness
The IVE estimates ranged between 34.0% and 40.6% 
in 2015/16, 8.5% and 9.7% in 2016/17, and 19.5% and 
23.8% in 2017/18 (Table 2). In the 2016/17 season, 
when influenza A(H3N2) virus was circulating in all 
countries, the IVE among the population 65 years and 
older was notably lower compared with other seasons.
Impact of influenza vaccination in the 
prevention of medically attended influenza-
confirmed cases
Number of averted events
Among those aged 65 years and older, influenza vacci-
nation prevented an average per season of 715 MAICC in 
Portugal, 5,042 in Spain, and 6,457 in the Netherlands 
(Table 3). In Portugal, Spain and the Netherlands, the 
NAE per 100,000 population 65 years and older was 
30, 61 and 275 in the 2015/16 season, 24, 24 and 69 in 
the 2016/17 season and 44, 88 and 268 in the 2017/18 
season, respectively. The three seasons’ NAE rate was 
204 cases per 100,000 in the Netherlands, 58 cases 
per 100,000 in Spain and 33 cases per 100,000 in 
Portugal (Table 3).
Prevented fraction and number needed to vaccinate
The seasonal average estimates of MAICC prevented 
fractions were similar for the three countries. The PF 
ranged between 19.1% and 24.7%, in the 2015/16 sea-
son, between 4.9% and 6.1% in 2016/17 and between 
11.1% and 14.5% in 2017/18 (Table 3).
As expected, the number needed to vaccinate to pre-
vent one MAICC followed the pattern observed for 
NAE, with the lowest NNV values for season 2017/18 
and the highest for season 2016/17 in all countries 
(Supplementary Table S2).
Discussion
Our results suggest that during the 2015/16 to 2017/18 
seasons, the influenza vaccination programmes 
in Portugal, Spain and the Netherlands had a sus-
tained and positive impact on primary care MAICC 
in the population aged 65 years and older. The influ-
enza vaccination programmes prevented an annual 
average of 33–204 primary care MAICC per 100,000 
and 10.7–14.2% of potential MAICC that would have 
occurred without vaccination programme.
The impact of the influenza vaccination programmes 
varied across the influenza seasons. We obtained 
MAICC prevented fractions in the 2015/16 season of 
19.1–24.7%, comparable to a study conducted in the 
United States (US) in 2013 that reported an average 
prevented fraction of 18.4% over six seasons [11].
We observed the lowest NAE during the 2016/17 sea-
son, when influenza A(H3N2) dominated in all coun-
tries. Given that VC did not vary considerably in the 
three seasons, the main drivers for the differences in 
season-specific NAE would be the number of MAICC 
and the IVE estimates. Seasons with dominant influ-
enza A(H3N2) circulation are reported to produce a high 
influenza burden in the elderly population [25], and 
often a limited IVE against subtype A(H3N2) [26,27]. In 
2016/17, the IVE was below 10% in the three countries. 
Despite this low protection, our results suggest that 
influenza vaccination programmes averted 24, 24 and 
69 primary care MAICC per 100,000 population among 
those aged 65 years and older in Portugal, Spain and 
the Netherlands, respectively. This is consistent with 
other studies where, even in seasons with low vaccine 
effectiveness, the vaccination programme was able 
to avert influenza consultations, hospitalisations and 
deaths [2,9,28]. Particularly for the influenza vaccine 
with often limited effectiveness [26,29], such a mes-
sage might illustrate considerable vaccine impact at 
population level, even when the vaccine effect at indi-
vidual level is suboptimal.
Also the prevented proportion of primary care MAICC 
was the lowest in the 2016/17 season, namely 4.9% in 
Portugal, 5.0% in Spain and 6.1% in the Netherlands. 
A similar low PF (7–11%) was estimated in the US for 
seasons with predominant influenza A(H3N2) circula-
tion [30,31]. The NAE results also differed by country, 
with Spain and Portugal both showing lower estimates 
than the Netherlands. As NAE is a linear function of pri-
mary care MAICC, a large difference in MAICC across 
countries or across seasons will lead to a large NAE 
difference.
In this study, we estimated the MAICC using primary 
care surveillance data. Potential explanations for the 
observed differences could be (i) the influenza posi-
tivity rate, (ii) the methods of the surveillance system, 
e.g. the case definition used to recruit ILI cases from 
the health system and (iii) the healthcare seeking 
behaviour.
The percentage of positive influenza cases among all 
tested varies between seasons and between countries, 
depending mainly on the (sub)type of the circulating 
virus and the sentinel GPs’ swabbing practice. The 
positivity pattern in the three countries was similar, 
with the highest positivity rate in the 2017/18 season, 
when influenza B virus accounted for more than 65%. 
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The opposite was observed in 2016/17, when almost all 
isolates were influenza A(H3N2). This subtype is more 
frequent among older adults in whom ILI rates are gen-
erally lower [32], which could explain a lower positivity 
rate.
Differences among countries can be derived from differ-
ent (sub)type distributions in the circulating virus and 
also from different real swabbing practices between 
countries, even if, as in our study, systematic swabbing 
is established in the three countries. Another source of 
differences is the correction of the Dutch positivity rate 
for the RT-PCR sensitivity. Given that the RT-PCR sensi-
tivity rate used was 95%, this would represent a sys-
tematic relative increase of 5.3% (1/0.95) in the Dutch 
positivity rates. This small increase does not explain 
the different NAE rate between countries.
Differences in national surveillance protocols may 
also play a role, e.g. the ILI case definition: In the 
Netherlands, the ILI case definition requires a 
fever ≥ 38 °C, while the EU ILI case definition used in 
Spain and Portugal only requires ’fever or feverish-
ness’. Fever may be associated with more severe ill-
ness and with a higher likelihood of healthcare use 
[33,34]. In addition, the identification of ILI patients 
and the selection of patients for swabbing rely on the 
GP’s criteria, which may be influenced by how influ-
enza surveillance has been done historically in their 
country, regardless of the ILI case definition used. 
Another important factor contributing to the different 
MAICC is probably the healthcare seeking behaviour 
in the age group 65 years and older. The use of pri-
mary healthcare has been described to be the highest 
in the Netherlands among the three countries [35]. In 
Portugal, the general population often uses emergency 
rooms at hospitals to treat acute illness [36], while in 
Spain and the Netherlands, the GP is the first point of 
call for an influenza consultation [37,38].
This study has limitations. One is the approach used 
to measure the impact assuming no indirect effect, 
i.e. no herd protection conferred by the vaccinated 
population to the non-vaccinated population. Dynamic 
model simulations have demonstrated that the indirect 
effect may not be negligible, particularly regarding the 
effect of vaccinating children on the adult population 
[39,40]. A meta-analysis revealed that influenza vacci-
nation in children may result in herd protection for the 
community-dwelling elderly population against influ-
enza-associated mortality [41]. However, to observe 
this herd protection in the population aged 65 years 
and older, a minimum VC of 20% is needed in chil-
dren [39]. In our study, the indirect effect may be small 
since there is no overall vaccination recommendation 
for the younger population in any of the three countries 
and VC in adults younger than 65 years is presumably 
low. In Portugal for instance, the VC in all three sea-
sons was below 5% in the 0–15 year-olds and between 
7% and 18% in adults younger than 65 years [21]. In 
the Netherlands VC was 10% for the total population 
aged 18–64 years in the 2017/18 season [19]. However, 
non-vaccinated elderly people may still benefit from 
vaccination of younger age groups, particularly in set-
tings with high VC in those 65 years and older [39]. As 
such, the NAE estimated in this study may be under-
estimated and the real impact of the vaccination pro-
gramme could be even higher.
Another component that is not accounted for in our 
approach is that part of the estimated impact outcome 
measures may be attributable to previously acquired 
immunity, either through vaccination or natural infec-
tion. Our method does not allow us to distinguish 
which proportion among the prevented fraction is due 
to previous immunity and which is due to the current 
seasonal vaccination.
Another limitation to be acknowledged are the different 
ILI definitions and sources to estimate the VC, where 
some countries used population-based surveys, others 
GP surveys or administrative registries. In Portugal and 
the Netherlands, only the VC of community-dwelling 
elderly population is captured.
In Spain, regional administrative registries were used 
to calculate the national influenza VC. In the majority 
of the regions, the registry includes vaccines adminis-
tered in both the public and the private sector. Only a 
few small regions report only vaccines administered in 
the public sector, therefore, we expect that influenza 
VC used reflected the VC in the population.
The study has several noteworthy strengths. Firstly, 
we used population-based surveillance data, so that 
the study can be replicated in several seasons and the 
results generalised for the population. Secondly, the 
IVE estimates derived from European pooled estimates 
were specific to the influenza (sub)type and adjusted to 
virus circulation in the country. This procedure not only 
allows us to obtain more precise estimates but also 
increases the robustness of the NAE results. Finally, 
we used country-specific data for all three countries 
individually, with harmonised analytical methods and 
definitions, allowing direct inter-country comparison.
Conclusion
The development of the common protocol resulted in a 
comparable population-based indicator of the impact 
of influenza vaccination programmes in the three 
countries. This can benefit existing influenza surveil-
lance systems which already capture the annual influ-
enza burden through national surveillance as well as 
estimation of the IVE through the I-MOVE network. 
Furthermore, by including severe influenza outcomes 
in future impact estimations, such as hospitalisations 
and deaths related to influenza, we will be able to pro-
vide a comprehensive view of the annual burden of 
influenza-related morbidity and mortality averted by 
vaccination.
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These results are important to support public health 
communication aiming to increase VC in high-risk 
groups. Influenza vaccination programmes can gain 
impact by increasing VC and/or IVE. Quantifying the 
benefit of annual vaccinations through estimates of 
their impact may contribute to this public health chal-
lenge, which could be a key message to the general 
public and decision makers, particularly in seasons 
with low vaccine effectiveness.
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